• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

369
66
48
46
21

COUNTRY

45
12
6
5
5

PRICE

287
485
868
1,339

PUBLISHED

24
147
425
1,339

PRODUCT TYPE

1,306
17
11
5

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Dystonia - Pipeline Review, H2 2014

Dystonia - Pipeline Review, H2 2014 Summary This, ‘Dystonia - Pipeline Review, H2 2014’, provides an overview of the Dystonia’s therapeutic pipeline. This report provides comprehensive information...

September 2014
FROM
Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers:  New Developments, Growth Areas and Opportunities - Product Thumbnail Image

Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities

This report is a comprehensive analysis and market study of the drug development pipeline relating to Alzheimer's Disease, which has been analysed alongside commercially available or developmental minimally-invasive...

September 2014
FROM

Perception Journal

Perception is a scholarly journal reporting experimental results and theoretical ideas ranging over the fields of human, animal, and machine perception Topics covered include physiological mechanisms...

September 2014
FROM

Neurotech Business Report

Neurotech Business Report is the first publication targeting the business of neurotechnology, the application of engineering techniques to human neural and information processing systems Each monthly...

September 2014

Neurological Research

10 issues per year Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences...

September 2014
FROM

Nutritional Neuroscience

"6 issues per year (Online Only) Nutritional Neuroscience is an international, interdisciplinary broad-based journal for reporting both basic and clinical research in the field of nutrition that relates...

September 2014
FROM
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies - Product Thumbnail Image

Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders Drugs may be administered directly into the CNS or administered systematically (e g ,...

September 2014
FROM
Alzheimer Disease - New Drugs, Markets and Companies Alzheimer Disease - New Drugs, Markets and Companies - Product Thumbnail Image

Alzheimer Disease - New Drugs, Markets and Companies

Alzheimer's disease remains a challenge in management With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future Considerable...

September 2014
FROM

Neurotech Insights

Covering Drugs, Devices, and Diagnostics for the Brain and Nervous System On the first day of each month, Neurotech Insights is delivered to your inbox giving you competitive intelligence on...

September 2014
FROM

Postherpetic Neuralgia - Pipeline Review, H2 2014

Postherpetic Neuralgia - Pipeline Review, H2 2014 Summary This, ‘Postherpetic Neuralgia - Pipeline Review, H2 2014’, provides an overview of the Postherpetic Neuralgia’s therapeutic pipeline. This...

August 2014
FROM

Opium (Opioid) Addiction - Pipeline Review, H2 2014

Opium (Opioid) Addiction - Pipeline Review, H2 2014 Summary This, ‘Opium (Opioid) Addiction - Pipeline Review, H2 2014’, provides an overview of the Opium (Opioid) Addiction’s therapeutic pipeline. This...

August 2014
FROM

Acute Ischemic Stroke - Pipeline Review, H2 2014

Acute Ischemic Stroke - Pipeline Review, H2 2014 Summary This, ‘Acute Ischemic Stroke - Pipeline Review, H2 2014’, provides an overview of the Acute Ischemic Stroke’s therapeutic pipeline. This report...

August 2014
FROM

Dyskinesia - Pipeline Review, H2 2014

Dyskinesia - Pipeline Review, H2 2014 Summary This, ‘Dyskinesia - Pipeline Review, H2 2014’, provides an overview of the Dyskinesia’s therapeutic pipeline. This report provides comprehensive information...

August 2014
FROM

Epilepsy - Pipeline Review, H2 2014

Epilepsy - Pipeline Review, H2 2014 Summary This, ‘Epilepsy - Pipeline Review, H2 2014’, provides an overview of the Epilepsy’s therapeutic pipeline. This report provides comprehensive information...

August 2014
FROM
Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014  Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 - Product Thumbnail Image

Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014

REPORT DESCRIPTION This report is a comprehensive analysis and market study of new developments relating to early-stage minimally-invasive biomarkers in Alzheimer's disease, which have been 'functionally...

August 2014
FROM

Visceral Pain - Pipeline Review, H2 2014

Visceral Pain - Pipeline Review, H2 2014 Summary This, ‘Visceral Pain - Pipeline Review, H2 2014’, provides an overview of the Visceral Pain’s therapeutic pipeline. This report provides comprehensive...

August 2014
FROM

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2014

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2014 Summary This, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2014’, provides an overview of the Dementia...

August 2014
FROM

Binge Eating Disorder - Pipeline Review, H2 2014

Binge Eating Disorder - Pipeline Review, H2 2014 Summary This, ‘Binge Eating Disorder - Pipeline Review, H2 2014’, provides an overview of the Binge Eating Disorder’s therapeutic pipeline. This report...

August 2014
FROM

Chronic Back Pain - Pipeline Review, H2 2014

Chronic Back Pain - Pipeline Review, H2 2014 Summary This, ‘Chronic Back Pain - Pipeline Review, H2 2014’, provides an overview of the Chronic Back Pain’s therapeutic pipeline. This report provides...

August 2014
FROM

Narcolepsy - Pipeline Review, H2 2014

Narcolepsy - Pipeline Review, H2 2014 Summary This, ‘Narcolepsy - Pipeline Review, H2 2014’, provides an overview of the Narcolepsy’s therapeutic pipeline. This report provides comprehensive information...

August 2014
FROM
Loading Indicator

Our Clients

Our clients' logos